From: The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer
Parameter
p0
10%
p1
30%
α
5%
β
Number of patients
Stage I
18
Stage II
17
Rejection of therapy
0 - 2 responder among 18 patients
0 - 6 responder among 35 patients